Effects of mycophenolate sodium with or without FTY720 in a DA-to-Lewis rat heart transplantation model.
Matsumoto
Y
Y
Novartis Pharma Research, Novartis Pharma AG, Basel, Switzerland.
Hof
R P
RP
D000818:Animals; D004195:Disease Models, Animal; D004359:Drug Therapy, Combination; D000068876:Fingolimod Hydrochloride; D006085:Graft Survival / Q000187:drug effects / Q000276:immunology*; D016027:Heart Transplantation / Q000276:immunology*; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D009173:Mycophenolic Acid / Q000627:therapeutic use*; D011409:Propylene Glycols / Q000627:therapeutic use*; D051381:Rats; D011917:Rats, Inbred Lew; D011919:Rats, Inbred Strains; D013110:Sphingosine / Q000031:analogs & derivatives; D013997:Time Factors; D014184:Transplantation, Homologous
D007166:Immunosuppressive Agents; D011409:Propylene Glycols; D000068876:Fingolimod Hydrochloride; D009173:Mycophenolic Acid; D013110:Sphingosine